Q-omics provides the consensus-scored GLRXP1 profile across patient tissues and cancer cell-line models. GLRXP1 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, GLRXP1 is differentially expressed in 2, with the highest sampling consensus in COAD. Additionally, GLRXP1 RNA expression shows 5,535 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KICH, COAD, and STAD as cancer lineages where GLRXP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GLRXP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GLRXP1 survival associations across molecular data types. GLRXP1 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GLRXP1 RNA expression–survival associations across cancer types. High GLRXP1 expression shows unfavorable associations in KICH, UCEC, UCS, THCA, DLBC and ACC. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for GLRXP1 RNA expression.
This table summarizes GLRXP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for GLRXP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GLRXP1 shows lower tumor expression in KICH and higher tumor expression in COAD. The COAD box plot shows higher GLRXP1 RNA expression in tumor versus normal tissue (log2 FC = +0.169, t-test p = .028).
This table shows molecular features associated with GLRXP1 in patient tissues and cancer cell lines. In patient samples, GLRXP1 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
